Status:

WITHDRAWN

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma

Lead Sponsor:

American Scitech International

Collaborating Sponsors:

Eli Lilly and Company

Bristol-Myers Squibb

Conditions:

Colorectal Carcinoma

Eligibility:

All Genders

40+ years

Phase:

PHASE2

Brief Summary

RATIONALE: Monoclonal antibodies, such as Cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.This is an anti-cancer drug wh...

Detailed Description

OBJECTIVES: Primary: * Determine the response rate in patients with Colorectal Cancer treated with Cetuximab and Radiation Therapy Vs Surgery before or after Radiation Therapy. Secondary: * To det...

Eligibility Criteria

Inclusion

  • Patients with stage II- IV Colorectal Cancer
  • Patients must be 40 years and older
  • Patients may be of any race and either gender
  • Signed Informed Consent
  • Patient characteristics:
  • Age: 40 years and older
  • Sex: Both
  • Performance status: Not specified
  • Life expectancy: Not specified
  • Hematopoietic:
  • Granulocyte count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Hemoglobin ≥ 9.0 g/dL
  • No history of significant bleeding events within the past 6 months
  • Hepatic:
  • Bilirubin ≤ 1.5 mg/dL
  • Albumin ≥ 2.5 g/dL
  • Renal:
  • Creatinine ≤ 1.5 times upper limit of normal
  • Protein \< 1+ by urinalysis
  • Protein \< 1 g by 24-hour urine collection
  • Cardiovascular:
  • No conduction defect in heart
  • No congestive heart failure
  • No myocardial infarction within last 6 months
  • No cerebrovascular accident
  • No uncontrolled hypertension
  • No clinically significant peripheral artery disease
  • Pulmonary:
  • No pulmonary embolism
  • No interstitial pneumonia
  • No extensive or symptomatic interstitial fibrosis of the lung
  • Neurologic:
  • No uncontrolled seizure disorder
  • No active neurological disease
  • Other:
  • Not pregnant or nursing
  • Negative pregnancy test

Exclusion

  • Age below 40 years
  • Brain or nervous system metastases
  • Any current mental illness
  • Hemoglobin is less than 9.0 g/dl
  • CBC results are below normal range
  • Patients with Hepatitis B or C or who are HIV positive
  • Pregnant or nursing patients are not eligible for entry into the study
  • Hepatic abnormality AST/ALT \> 4 folds

Key Trial Info

Start Date :

February 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2014

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT00725400

Start Date

February 1 2010

End Date

February 1 2014

Last Update

July 20 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Practicing Physician in New Jersey

Englishtown, New Jersey, United States, 07726